Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» IPOs
IPOs
Biopharma’s top 5 IPOs of 2023 (so far)
Biopharma’s top 5 IPOs of 2023 (so far)
Pharma Voice
biotech
IPOs
Acelyrin
Apogee Therapeutics
RayzeBio
Neumora Therapeutics
Mineralys Therapeutics
Flag link:
Playing in the Hot Obesity Market, Carmot Braves Chilly IPO Waters
Playing in the Hot Obesity Market, Carmot Braves Chilly IPO Waters
BioSpace
Carmot Therapeutics
obesity
IPOs
Flag link:
WuXi Biologics bioconjugates spinout plans $470 million IPO
WuXi Biologics bioconjugates spinout plans $470 million IPO
Biopharma Reporter
WuXi Biologics
IPOs
spinoffs
WuXi XDC
CRDMOs
Flag link:
IPO Update: Cargo Therapeutics Readies Plans For $300 Million IPO
IPO Update: Cargo Therapeutics Readies Plans For $300 Million IPO
Seeking Alpha
Cargo Therapeutics
IPOs
large B cell lymphoma
Flag link:
WuXi Biologics' medical research unit eyes up to $471 million in Hong Kong IPO
WuXi Biologics' medical research unit eyes up to $471 million in Hong Kong IPO
Reuters
WuXi XDC
IPOs
Hong Kong
WuXi Biologics
Flag link:
Lexeo drops share price at last minute in attempt to raise $100M IPO
Lexeo drops share price at last minute in attempt to raise $100M IPO
Fierce Biotech
Lexeo Therapeutics
IPOs
gene therapy
Flag link:
Lessons from a biotech downturn: Funding challenges, an IPO dry spell and what to expect in 2024
Lessons from a biotech downturn: Funding challenges, an IPO dry spell and what to expect in 2024
BioPharma Dive
biotech
funding
IPOs
Flag link:
5 financial challenges facing the medtech sector
5 financial challenges facing the medtech sector
Medtech Dive
Medtech
revenue
M&A
spinoffs
funding
IPOs
Flag link:
How biotech IPOs performed in the third quarter
How biotech IPOs performed in the third quarter
BioPharma Dive
biotech
IPOs
Adlai Nortye
RayzeBio
Neumora Therapeutics
Mira Pharmaceuticals
Turnstone Biologics
Apogee Therapeutics
Sagimet Biosciences
60 Degrees Pharma
Flag link:
Lexeo, Abivax File for IPOs on Nasdaq Amid Industry-Wide Drought
Lexeo, Abivax File for IPOs on Nasdaq Amid Industry-Wide Drought
BioSpace
IPOs
Lexeo Therapeutics
Abivax
genetic medicine
Flag link:
Adlai Nortye IPO gives old Novartis cancer drug new life
Adlai Nortye IPO gives old Novartis cancer drug new life
BioPharma Dive
Adlai Nortye
IPOs
Novartis
AN2025
head and neck cancer
solid tumors
Flag link:
Neumora Therapeutics stock surges as Amgen confirmed as major shareholder
Neumora Therapeutics stock surges as Amgen confirmed as major shareholder
Proactive Investors
Amgen
Neumora
IPOs
Flag link:
Emcure Pharma plans to launch $400-500 million IPO in 2024
Emcure Pharma plans to launch $400-500 million IPO in 2024
Mint
Emcure Pharmaceuticals
IPOs
Flag link:
Antibody biotech Abpro taps SPAC to get back on Nasdaq track 5 years after axed IPO
Antibody biotech Abpro taps SPAC to get back on Nasdaq track 5 years after axed IPO
Fierce Biotech
AbPro
IPOs
SPAC
NASDAQ
Flag link:
Biotech Financing, IPO Tide May Be Turning – Signs of a Potential Recovery?
Biotech Financing, IPO Tide May Be Turning – Signs of a Potential Recovery?
BioSpace
biotech
IPOs
Neumora Therapeutics
Rome Therapeutics
Generate Biomedicines
Flag link:
RayzeBio, Neumora price some of biotech’s largest IPOs this year
RayzeBio, Neumora price some of biotech’s largest IPOs this year
BioPharma Dive
IPOs
RayzeBio
Neumora Therapeutics
Flag link:
SoftBank-backed Neumora Therapeutics aims to raise up to $264.8 mln in US IPO
SoftBank-backed Neumora Therapeutics aims to raise up to $264.8 mln in US IPO
NASDAQ
Neumora Therapeuticsl
funding
Japan
SoftBank
IPOs
Flag link:
Neumora, a richly funded brain drug developer, readies for an IPO
Neumora, a richly funded brain drug developer, readies for an IPO
BioPharma Dive
Neumora Therapeutics
IPOs
depression
navacaprant
Flag link:
RayzeBio plans IPO to push radiotherapy 'pipeline-in-a-product' through phase 3
RayzeBio plans IPO to push radiotherapy 'pipeline-in-a-product' through phase 3
Fierce Biotech
Rayze Bio
radiotherapy
IPOs
Flag link:
In a year with few biotech IPOs, ‘crossover’ financings are hard to find
In a year with few biotech IPOs, ‘crossover’ financings are hard to find
BioPharma Dive
CG Oncology
cancer
IPOs
funding
crossover financing
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »